Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) COO Robert Paul Discordia acquired 2,500 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were acquired at an average cost of $4.62 per share, with a total value of $11,550.00. Following the completion of the transaction, the chief operating officer now directly owns 32,650 shares in the company, valued at approximately $150,843. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Corbus Pharmaceuticals stock traded up $0.01 during midday trading on Friday, reaching $4.30. 1,231,900 shares of the stock traded hands, compared to its average volume of 710,125. The company has a current ratio of 1.88, a quick ratio of 2.56 and a debt-to-equity ratio of 0.27. Corbus Pharmaceuticals Holdings Inc has a 12-month low of $4.18 and a 12-month high of $9.11. The company has a 50-day simple moving average of $4.93 and a two-hundred day simple moving average of $6.04. The firm has a market cap of $281.97 million, a PE ratio of -4.39 and a beta of 1.87.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. Corbus Pharmaceuticals had a negative return on equity of 169.38% and a negative net margin of 175.16%. The business had revenue of $2.59 million for the quarter, compared to the consensus estimate of $1.73 million. Equities research analysts anticipate that Corbus Pharmaceuticals Holdings Inc will post -1.06 earnings per share for the current year.

A number of analysts recently issued reports on the company. ValuEngine downgraded Corbus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, August 2nd. BidaskClub downgraded Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday. Royal Bank of Canada reissued a “buy” rating and set a $23.00 price objective on shares of Corbus Pharmaceuticals in a research report on Sunday, August 11th. Finally, Zacks Investment Research downgraded Corbus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. Corbus Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $23.71.

Several large investors have recently modified their holdings of CRBP. ETF Managers Group LLC purchased a new stake in shares of Corbus Pharmaceuticals in the second quarter valued at $48,587,000. BlackRock Inc. increased its stake in Corbus Pharmaceuticals by 5.0% in the second quarter. BlackRock Inc. now owns 5,284,629 shares of the biopharmaceutical company’s stock valued at $36,623,000 after purchasing an additional 253,676 shares during the last quarter. Vanguard Group Inc. increased its stake in Corbus Pharmaceuticals by 7.7% in the second quarter. Vanguard Group Inc. now owns 3,080,166 shares of the biopharmaceutical company’s stock valued at $21,346,000 after purchasing an additional 220,625 shares during the last quarter. Russell Investments Group Ltd. acquired a new position in Corbus Pharmaceuticals in the third quarter valued at $1,062,000. Finally, AE Wealth Management LLC acquired a new position in Corbus Pharmaceuticals in the second quarter valued at $755,000. Institutional investors and hedge funds own 50.33% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis.

See Also: How are Outstanding Shares Different from Authorized Shares?

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.